Navigation Links
Cambrex Reports Fourth Quarter and Full Year 2009 Results
Date:2/10/2010

ables, loss on disposition of assets, cancellation or delays in renewal of contracts, lack of suitable raw materials or packaging materials, the Company's ability to receive regulatory approvals for its products and other factors described under the caption "Risk Factors That May Affect Future Results" in the Company's Quarterly Report on Form 10-Q for the period ending September 30, 2009.  Any forward-looking statement speaks only as of the date on which it is made, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.  New factors emerge from time to time and it is not possible for the Company to predict which will arise.  In addition, the Company cannot assess the impact of each factor on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

For further details and a discussion of these and other risks and uncertainties, investors are cautioned to review the Cambrex 2008 Annual Report on Form 10-K, including the Forward-Looking Statement section therein, and other filings with the U.S. Securities and Exchange Commission.  The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

About Cambrex

Cambrex provides products and services to accelerate the development and commercialization of small molecule therapeutics including APIs, advanced intermediates, enhanced drug delivery, and other products for branded and generic pharmaceuticals.  The Company currently employs approximately 850 people worldwide.  For more information, please visit

SOURCE Cambrex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Cambrex Presentation at the JPMorgan Healthcare Conference to be Webcast
2. Cambrex to Announce Fourth Quarter and Full Year 2007 Financial Results on February 14, 2008
3. Cambrex Appoints Steven M. Klosk as President and CEO
4. Cambrex Reports Third Quarter 2008 Results
5. Cambrex Receives Notice Regarding NYSE Listing
6. Cambrex Reports First Quarter 2009 Results
7. Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Nominated for 2009 Innovations Award
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 18, 2014 Relmada Therapeutics, Inc. (OTCQB: RLMD), ... of chronic pain, announced the results of its annual ... was a transformational year in Relmada,s history and it ... company," said Sergio Traversa , chief executive officer ... on key financial, human resource and clinical development objectives ...
(Date:12/17/2014)... Houston, TX (PRWEB) December 17, 2014 ... marketing and administration for Stoller Group. In this position, ... Stoller Group, on administrative matters, develop marketing strategy and ... and services. , “Achim has tremendous knowledge and ... president of Stoller Group. “His experience and innovative thinking ...
(Date:12/17/2014)... Xeno Diagnostics has again received an ... COLA inspection. Xeno has met all criteria for ... organization. Accreditation is earned only by laboratories that ... demonstrate continued accuracy in the performance of proficiency ... , While the Laboratory Excellence award ...
(Date:12/17/2014)... Md. , Dec. 17, 2014  United Therapeutics ... senior executive promotions as well as changes to ... Senior Executive Promotions United Therapeutics announced ... President and Co-Chief Executive Officer and David Zaccardelli ... Officer.  In connection with these promotions, Dr. Rothblatt,s title ...
Breaking Biology Technology:Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 2Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4
... Engineering Technology to Bring New Choices, More Options to Global ... ... and RESEARCH TRIANGLE PARK, N.C., Feb. 11,/PRNewswire- FirstCall/ -- DuPont (NYSE: ... to bring higher-yielding,agricultural products to the market faster. Terms of the ...
... 11 On February 8, Michael F. Brigham,President ... ) (http://www.immucell.com ),updated the investment community in ... in the interview include an overview of the,company, ... for,which investors should watch., To hear the ...
... to gently clean and help heal ... ... today,announced that it has launched the Qoustic Wound Therapy System(TM), which,advances ... a safe, cost-effective alternative to painful sharps,debridement and other surgical modalities. ...
Cached Biology Technology:DuPont and Precision BioSciences Collaborate to Accelerate Crop Product Development 2WallSt.net Updates Investment Community Through All-New Interview With ImmuCell 2Arobella Medical, LLC Launches Qoustic Wound Therapy System(TM) 2Arobella Medical, LLC Launches Qoustic Wound Therapy System(TM) 3
(Date:12/3/2014)... Dec. 2, 2014 As part of our ... Technologies is pleased to announce the release of a ... to collect the workforce data that they need. ... been left by existing readers. Many such devices have ... and modern technology. Older models force users to navigate ...
(Date:11/21/2014)... 2014   Atmel® Corporation (NASDAQ: ... touch technology solutions, today launched the industry,s first family ... widest V cc range from 1.7V to 5.5V. ... I 2 C bus communication speeds, and are available ... them ideal for consumer, industrial, computer, and medical applications. ...
(Date:11/15/2014)... 13, 2014  While we may still be a few ... in "Star Trek" to gain instant access to all that ... with smartphones and tablets for monitoring and measuring our health ... This may seem a tad Orwellian to some, but a ... of these technological opportunities into their healthcare regime. ...
Breaking Biology News(10 mins):Inception Technologies to Release New Biometric Reader 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4
... Education for All) argues that the education of children ... and nutrition, which have reduced major diseases in poor ... Matthew Jukes, one of the books authors says: ... in schools, wed go a long way to enabling ...
... M2SYS Fingerprint Technology to ... Accurately Verify Check Casher Identity, ATLANTA, Sept. ... development firm, announced today its partnership,with TeraCorp Enterprises, a ... the M2SYS Bio-Plugin(TM) fingerprint,solution into TeraCash, a cutting-edge check ...
... the latest horticulture research on high tunnels, ... The American Society for Horticultural Science (ASHS) ... horticulture presentations from the 2007 ASHS Annual ... broad selection of horticulture presentations by world-class ...
Cached Biology News:Leading experts cite poor health and nutrition as major barrier to education in developing world 2M2SYS Technology Partners with TeraCorp Enterprises to Provide Added Security Within Check Cashing Solution 2HortTalks, a valuable scientific resource 2
... tool provides the firm pressure necessary ... in tubes or plates. The multifunctional ... that firmly holds thin-wall 0.5 ml ... opening or closing. A side slot ...
... USP is a highly nutritious versatile medium ... Due to the inclusion of both Tryptone ... growth of many fastidious organisms without the ... to United States Pharmacopeia standards for use ...
...
... B-Bridge's siSolutions RNAi Services offer ... for your siRNA studies. B-Bridges advanced ... and technical expertise ensure that you ... experiments. siSolutions siRNA Design Service utilizes ...
Biology Products: